MedTrace Logo

Effectiveness of Smartphone Application for Adherence Support (Vuka+)

NCT06897059 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2025-03-26

No results posted yet for this study

Summary

This is a Type I Hybrid effectiveness-implementation trial to evaluate an HIV Pre-Exposure Prophylaxis (PrEP) medication adherence, persistence and social support app (Vuka+) for adolescent girls and young women (AGYW) in South Africa. This 6-month, 2-arm effectiveness and implementation trial (standard of care \[SOC\] vs. intervention app) will assess acceptability, feasibility and effectiveness. In addition, we will gather information on intervention delivery and barriers and facilitators for real-world delivery to inform future implementation and scale up.

Conditions

  • Adherence, Medication
  • Smartphone Application

Interventions

OTHER

Vuka+ application

The Vuka+ smartphone app included PrEP daily reminders, tracking for pill taking, resources for sexual reproductive health including quizzes and articles, and chat access to other Vuka+ users and medical expert.

Sponsors & Collaborators

  • CONRAD

    collaborator OTHER

  • Desmond Tutu Health Foundation

    collaborator OTHER

  • Florida State University

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • United States Agency for International Development (USAID)

    collaborator FED

  • Gilead Sciences

    collaborator INDUSTRY

  • Old Dominion University

    collaborator OTHER

  • Eastern Virginia Medical School

    lead OTHER

Principal Investigators

  • Homaira Hanif, PhD · CONRAD/EVMS

  • Kathryn Muessig, PhD · FSU

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2024-03-01
Completion
2024-11-08

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06897059 on ClinicalTrials.gov